Aldeyra Therapeutics Receives FDA Special Protocol Assessment for ADX-2191 in Primary Vitreoretinal Lymphoma

Aldeyra Therapeutics announced that it received a Special Protocol Assessment Agreement from the FDA for ADX-2191, a novel formulation of methotrexate...

Empowering Life Sciences with
Advanced AI Solutions.

Book A Demo
HomeKnolsightsContact UsPricing
One Research Ct, Suite 450 Rockville, MD, 20850
info@pienomial.com
+91 9876543210
Copyright © 2025. All rights reserved
AboutTerms of ServicePrivacy Policy
Home/KnloSights/Clinical Trial Updates/Aldeyra Therapeutics Receives FDA Special Protocol Assessment for ADX-2191 in Primary Vitreoretinal Lymphoma